Atorvastatin in Moderate Active Crohns Disease

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Skane University Hospital
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Clinical diagnosis of Crohns disease

• C-reactive protein level > 2 mg/L in absence of an infection

• Fecal calprotectin > 250 mg/kg or CDAI > 150

Exclusion Criteria:

• CDAI > 450

• Prednisolone dosage above 15 mg/day